SCHEMBL498474

SCHEMBL498474

Brc1ccc(-c2ccc(-c3ccc(Br)s3)s2)s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.48
MAPT P10636 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HSD17B10 Q99714 2/20 0.46
ALOX12 P18054 2/20 0.46
ALOX15 P16050 1/20 0.46
KDM4E B2RXH2 4/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
RXFP1 Q9HBX9 3/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 2/20 0.43
PPARG P37231 2/20 0.43
NCOA2 Q15596 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
NCOA1 Q15788 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889177 1.00 SNCA (0.48) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL5889194 1.00 SNCA (0.48) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL5453288 1.00 SNCA (0.48) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL197157 0.97 SNCA (0.50) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL16140274 0.91 SNCA (0.43) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL12964479 0.84 SNCA (0.39) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL8508163 0.84 MAPT (0.42) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL12964481 0.83 SNCA (0.38) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL2778388 0.81 SNCA (0.61) SNCAMAPTMEN1KMT2AHSD17B10
SCHEMBL4090912 0.81 MAPT (0.44) SNCAMAPTMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035592-A1 CATIONICALLY POLYMERIZABLE RESIN COMPOSITION FOR THREE-DIMENSIONAL PHOTOFABRICATION AND METHOD FOR PRODUCING THREE-DIMENSIONAL PHOTOFABRICATED PRODUCT TOKUYAMA DENTAL CORPORATION (JP) 2026-02-05 US disclosed
US-12202954-B2 Rubber composition and crosslinked rubber molded product SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2025-01-21 US disclosed
US-20240180788-A1 PHOTOCATIONICALLY CURABLE COMPOSITION TOKUYAMA DENTAL CORPORATION (JP) 2024-06-06 US disclosed
WO-2024038705-A1 CATIONICALLY POLYMERIZABLE RESIN COMPOSITION FOR 3D STEREOLITHOGRAPHY AND METHOD FOR PRODUCING 3D STEREOLITHOGRAPHY PRODUCT 株式会社トクヤマデンタル 2024-02-22 WO disclosed
EP-4310128-A1 PHOTOCATIONICALLY CURABLE COMPOSITION Tokuyama Dental Corporation (JP) 2024-01-24 EP disclosed
EP-4310128-A1 PHOTOCATIONICALLY CURABLE COMPOSITION Tokuyama Dental Corporation (JP) 2024-01-24 EP disclosed
US-20230114853-A1 RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2023-04-13 US disclosed
US-11312820-B2 Solution-processable indenofluorenes and methods to generate solution-processable indenofluorenes INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2022-04-26 US disclosed
US-20220081305-A1 CRYSTAL, METHOD OF PRODUCING CRYSTAL, AND METHOD OF SELF-ORGANIZING SILANOL COMPOUND NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2022-03-17 US disclosed
US-20210115187-A1 SOLUTION-PROCESSABLE INDENOFLUORENES AND METHODS TO GENERATE SOLUTION-PROCESSABLE INDENOFLUORENES INTERNATIONAL BUSINESS MACHINES CORPORATION 2021-04-22 US disclosed
US-20020061330-A1 Supports for photosensitizer formulations BRITISH COLUMBIA, THE UNIVERSITY OF (CA) 2002-05-23 US disclosed
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors QLT INC. (CA) 2002-02-21 US disclosed
WO-2001085212-A2 DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-11-15 WO disclosed
WO-2001035996-A2 USE OF PDT TO INHIBIT INTIMAL HYPERPLASIA QLT INC. (CA) 2001-05-25 WO disclosed
WO-2001035997-A2 USE OF LOW-DOSE PDT TO INHIBIT RESTENOSIS QLT INC. (CA) 2001-05-25 WO disclosed
EP-0668277-B1 Bipyridyl-oligothiophene derivatives as electron-conducting materials VALTION TEKNILLINEN (FI) 1998-11-04 EP disclosed
US-5556524-A DIAGNOSTICS VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) 1996-09-17 US disclosed
EP-0668277-A1 Bipyridyl-oligothiophene derivatives as electron-conducting materials VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) 1995-08-23 EP disclosed
US-5180838-A Terthienyl compounds as insecticides HER MAJESTY THE QUEEN AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1993-01-19 US disclosed
US-5045563-A Terthienyl Compound HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) 1991-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180788-A1 PHOTOCATIONICALLY CURABLE COMPOSITION CRY1, CRY2, TYR SNCA 1582/4885MAPT 162/4885MEN1 1163/4885
US-11312820-B2 Solution-processable indenofluorenes and methods to generate solution-processable indenofluorenes INF2, ABL1, ICMT SNCA 1576/4885MAPT 3729/4885MEN1 3665/4885
US-20020061330-A1 Supports for photosensitizer formulations PPOX, PPIF, SDHA SNCA 2565/4885MAPT 1710/4885MEN1 2343/4885
US-20210115187-A1 SOLUTION-PROCESSABLE INDENOFLUORENES AND METHODS TO GENERATE SOLUTION-PROCESSABLE INDENOFLUORENES INF2, ABL1, ICMT SNCA 1576/4885MAPT 3729/4885MEN1 3665/4885
US-20260035592-A1 CATIONICALLY POLYMERIZABLE RESIN COMPOSITION FOR THREE-DIMENSIONAL PHOTOFABRICATION AND METHOD FOR PRODUCING THREE-DIMENSIONAL PHOTOFABRICATED PRODUCT TERB1, CAD, C9 SNCA 4501/4885MAPT 510/4885MEN1 2791/4885
US-20020022032-A1 Immuno-adjuvant PDT treatment of metastatic tumors CD74, ANXA11, ANXA1 SNCA 4090/4885MAPT 1243/4885MEN1 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.